Abstract
Cell-to-cell spread of HIV, a directed mode of viral transmission, has been observed to be more rapid than cell-free infection. However, a mechanism for earlier onset of viral gene expression in cell-to-cell spread was previously uncharacterized. Here we used time-lapse microscopy combined with automated image analysis to quantify the timing of the onset of HIV gene expression in a fluorescent reporter cell line, as well as single cell staining for infection over time in primary cells. We compared cell-to-cell spread of HIV to cell-free infection, and limited both types of transmission to a two-hour window to minimize differences due to virus transit time to the cell. The mean time to detectable onset of viral gene expression in cell-to-cell spread was accelerated by 19% in the reporter cell line and by 35% in peripheral blood mononuclear cells relative to cell-free HIV infection. Neither factors secreted by infected cells, nor contact with infected cells in the absence of transmission, detectably changed onset. We recapitulated the earlier onset by infecting with multiple cell-free viruses per cell. Surprisingly, the acceleration in onset of viral gene expression was not explained by cooperativity between infecting virions. Instead, more rapid onset was consistent with a model where the fastest expressing virus out of the infecting virus pool sets the time for infection independently of the other co-infecting viruses.
Author Summary
How quickly infection occurs should be an important determinant of viral fitness, but mechanisms which could accelerate the onset of viral gene expression were previously undefined. In this work we use time-lapse microscopy to quantify the timing of the HIV viral cycle and show that onset of viral gene expression can be substantially accelerated. This occurs during cell-to-cell spread of HIV, a mode of directed viral infection where multiple virions are transmitted between cells. Surprisingly, we found that neither cooperativity between infecting viruses, nor trans-acting factors from already infected cells, influence the timing of infection. Rather, we show experimentally that a more rapid onset of infection is explained by a first-past-the-post mechanism, where the fastest expressing virus out of the infecting virus pool sets the time for the onset of viral gene expression of an individual cell independently of other infections of the same cell. Fast onset of viral gene expression in cell-to-cell spread may play an important role in seeding the HIV reservoir, which rapidly makes infection irreversible.
Introduction
Cell-to-cell spread of HIV is a mechanism of viral transmission whereby interaction between an infected donor cell and an infectable target cell leads to the directed transmission of virions to the target cell. Such interactions can occur between donor and target cells by various mechanisms [1–12], all of which involve the directed delivery of virions very close to the target cell, minimizing the distance over which virions need to diffuse and the consequent loss of virions en route [1–9, 11–24]. Because of the resulting high efficiency of viral delivery, target cells in cell-to-cell spread are exposed to multiple virions per cell both in in vitro infections and in vivo [17, 18, 25–31]. Multiple infections per cell decrease the sensitivity of cell-to-cell spread to antiretroviral drugs [17, 25, 27, 32, 33] and neutralizing antibodies [18, 34–36], and can overcome low infectivity and cellular restriction factors [37], since they increase the chances that at least one of the transmitted virions will successfully infect the cell despite inhibitors or unfavorable infection conditions [27, 38]. Because the source of insensitivity to inhibitors in cell-to-cell spread of HIV derives from multiple infections per cell, it is expected that sufficiently high inhibitor concentrations, or inhibitors more adept at suppressing multiple infections, could overcome this barrier [32, 33]. Conversely, cell-to-cell spread would offer a window of opportunity for HIV to evolve resistance to antiviral inhibitors [35].
As well as decreasing sensitivity to inhibitors, cell-to-cell spread of HIV was observed to be more rapid than cell-free infection [2, 13, 39–41]. One explanation may be fusion between donor and target cells. Fusion is insufficient for infection, as nucleic acids cannot directly infect a cell by translocating to the uninfected target cell [22]. However, the target cell would be scored as infected if a viral gene product or marker is used for detection, as fused cells share their protein pools and the marker would translocate to the target from the donor cell whether or not infection of the target cell took place. If fusion is excluded, acceleration of the viral cycle may be the result of several mechanisms: Shorter distance for the virus to transit before reaching a target cell, faster virus entry, faster pre- or post-integration dynamics due to cooperativity, and faster dynamics due to trans-acting factors secreted by the donor cells. Cooperativity would be expected to play a role in accelerating the virus cycle due to the Tat positive feedback loop [42–44], where Tat expressed from one provirus would trigger the transcript elongation of another provirus. Since the Tat protein can diffuse in and out of cells [43], such acceleration can also be potentially mediated in trans by the presence of nearby infected cells. Other HIV proteins, such as Nef, may also modify the physiology of yet uninfected cells upon cell-to-cell contact [45].
Another mechanism which can contribute to the acceleration of the viral cycle is probabilistic: since time to productive infection varies between virions due to integration site and stochastic gene expression [42, 44, 46, 47], cell-to-cell spread, which leads to multiple infections per cell, could increase the probability that at least one of the infecting viruses would have rapid infection dynamics.
Here we determined the timing of cell-to-cell spread and cell-free infection in a short infection time window, thereby limiting the role that the transit time to the target cell plays in infection timing. Despite this, we observed that cell-to-cell spread of HIV led to significantly earlier onset of viral gene expression. Surprisingly, we did not find evidence that factors secreted by donor cells, infected donor cell contact with target cells in the absence of transmission, or cooperativity between virions caused the earlier gene expression onset. We were able to replicate earlier onset in viral protein expression by increasing the multiplicity of infection with cell-free virus. This explains the observed rapid onset of viral gene expression of cell-to-cell spread by a mechanism where the fastest virus to be expressed sets the time of infection independently of other infections of the same cell.
Results
Cell-to-cell spread leads to earlier onset of HIV gene expression
In this study, we used the timing of the detectable onset of viral gene expression as a measure of the rate of the viral cycle. We used several ways to detect HIV gene expression, as summarized in S1 Table. Virus used for infection was produced from a molecular clone of the NL4-3 HIV strain to minimize any sequence differences between infecting virions. To compare the onset of cell-free infection to cell-to-cell spread, we infected target cells with either cell-free virus obtained from the filtered supernatant of virus producing cells, or by coculture with infected donor cells. In coculture, infection consists of a mix of cell-to-cell spread of HIV and cell-free infection. Hence, any observed difference between coculture and cell-free infection would be an underestimate of the difference between cell-to-cell spread and cell-free infection.
In order to quantify the onset of coculture versus cell-free infection by time-lapse microscopy, we imaged infection in the RevCEM cell line [48]. This cell line contains a GFP reporter that is responsive to the HIV splicing regulator protein Rev and hence reflects the timing of late HIV proteins [43, 49–51]. In order to efficiently detect infection, we subcloned the cell line to produce the reporter clone E7. This increased the maximum percentage of GFP positive cells from approximately 10% in the parental line to 70% in E7 (Fig 1A, left column). To enable the automated determination of the number of infected target cells (S1 Fig), we further stably expressed mCherry in these cells and derived the mCherry labelled G2 clone (Fig 1A, middle column). To exclude donor-target cell fusions, we labelled donor cells with the vital stain CellTrace Far Red (CTFR, Fig 1A, right column). CTFR and mCherry double positive cells were excluded from the analysis. In the absence of fusion exclusion, coculture infection showed a baseline from the earliest time points, which may not be real infection (S2 Fig).
We imaged infection over two days (S1 Movie). We used automated image analysis to determine the number of GFP+/mCherry+/CTFR- cells over the total number of mCherry+/CTFR- cells in each field of view at each frame of the movie (Fig 1B). In this experiment and the other time-lapse experiments performed in this study, we did not track individual cells, but rather measured the number of target cells with detectable viral gene expression at each time-point. We limited infection to the first two hours by washing away cell-free virus after that time window, and inhibiting additional infection cycles by addition of the protease inhibitor atazanavir (ATV), which has been described to effectively inhibit cell-to-cell transmission [33]. We imaged infection after washing and ATV addition. The protease inhibitor was used at a concentration that blocked over 99% of coculture infections (S3A Fig). This window for infection limited the time that the virus could transit to the target cell to no more than two hours in both coculture and cell-free infection. We calibrated the input of cell-free virus and infected cells so that the frequency of infected target cells after 48 hours was similar between the infection modes and did not saturate the available target cells (S4 Fig).
We quantified the fraction of infected cells over time and observed that both cell-free and coculture infection resulted in a variable time to Rev activity in individual infected cells, consistent with previous results showing heterogeneity in the length of the HIV replication cycle in cell-free infection [52]. In both infection modes, no Rev activity was detected before approximately 20 hours, corresponding to a period of intracellular delay [53–55]. On average, coculture infection showed more rapid HIV gene expression relative to cell-free infection (Fig 1C). We derived the mean and standard deviation for the timing of coculture and cell-free infections by parametrizing the number of infected cells over time with a best fit Gamma distribution, since Gamma distributions are a standard model for the timing of multi-step processes [56]. We obtained a time to detectable per cell Rev activity in coculture infection of 28±5.0 hours (mean±std). In contrast, mean time to per cell Rev activity in cell-free infection was 34.5±6.1 hours. This constituted an acceleration of 19% in the mean time to Rev activity in coculture infection. The difference between the two means was significant (p = 9x10-4, bootstrap).
Secreted factors and contact with infected cells in the absence of transmission do not accelerate HIV gene expression
We investigated the role of secreted factors acting in trans in the earlier onset of HIV gene expression by coculture with infected donor cells. To isolate the contribution of factors acting in trans, we separated infected donors from targets by a transwell membrane permeable to cell-free virus and soluble factors. We obtained no acceleration of time to detectable GFP expression using transwell infection (Fig 2A).
We considered the possibility that factors acting in trans may only operate over very short distances or that direct contact between donor and target cells, unrelated to viral transmission, may be required for an earlier onset of HIV gene expression. To test this, we took advantage of the fact that our reporter cell line could only be infected with HIV which uses the CXCR4 co-receptor. We therefore infected cells using the cell-free route with our CXCR4 tropic strain (NL4-3) in the presence of cocultured CD4+ cells infected with CCR5 tropic HIV (NL-AD8). This CCR5 tropic strain is identical to NL4-3, except for the Env protein, which is specific for the CCR5 co-receptor. We verified that NL-AD8 infected CD4+ cells could not infect the G2 target cells by coculture (S5 Fig). We did not observe a more rapid onset of HIV gene expression of cell-free infection cocultured with cells infected with the CCR5 tropic HIV compared to cell-free infection in the absence of these cells (Fig 2B), indicating that trans-acting factors are unlikely to induce an earlier onset of viral gene expression.
Multiple infections per cell result in earlier onset of HIV gene expression
We asked whether the higher force of infection in cell-to-cell spread, manifesting as multiple infections per target cell, leads to earlier onset of HIV gene expression. We therefore used concentrated cell-free virus to mimic the higher infection levels per cell observed in cell-to-cell spread. We used the highly infection permissive MT4 cell line [27] to enable infection at a multiplicity greater than 1 within a two-hour infection window. As a reporter for infection, we used the NL4-3YFP strain of HIV [57] which substitutes YFP for the HIV early gene Nef. Therefore, YFP expression reflects the timing of HIV early genes (S1 Table). We infected MT4 cells with NL4-3YFP cell-free virus (S2 Movie) at increasing multiplicities of infection (MOI) per target cell, starting at an MOI of 0.1 infectious units per cell and up to an MOI of 4. After two hours, we removed the residual virus by washing and added sufficient ATV to prevent additional infections from coculture (S3B Fig).
We observed a more rapid onset of YFP expression with increasing MOI, accelerating mean expression time from 27.5±6.1 hours at an MOI of 0.1, which results almost exclusively in infections with one virus, to 22.6±5.5 hours at an MOI of 4 (Fig 3A). This acceleration in onset relative to the 0.1 MOI infection was significant (p = 1.7x10-3 for MOI = 0.5, p<10−4 for MOI = 2 and MOI = 4 using bootstrap).
We asked whether this earlier onset was mediated by cooperativity: pre- or post-integration interactions between virions that would lead to faster HIV gene expression. For this, we compared MT4 cells infected with NL4-3YFP alone to MT4 cells co-infected with NL4-3YFP and the unlabeled NL4-3 strain of HIV. The unlabeled HIV infection was at high multiplicity (MOI = 8) to ensure that the majority of cells infected with the YFP reporter HIV were also co-infected with the unlabeled HIV. If cooperativity has a role in the more rapid onset of viral gene expression, the unlabeled virus should accelerate the expression of labelled virus to the threshold of detection. However, we observed that co-infection did not lead to a more rapid onset of YFP expression (Fig 3B).
MT4 cells are known to be infected with HTLV-I [58] and hence any lack of cooperativity due to co-infection may be the result of saturating cooperativity with the endogenous virus. We therefore proceeded to investigate cooperativity in the onset of HIV gene expression between co-infecting viruses in primary CD4+ T cells. To investigate cooperativity in this system, we co-infected cells by the cell-free route with HIV expressing YFP and HIV expressing CFP. We detected the number of infected cells by flow cytometry at 6 hour intervals. We obtained CFP and YFP singly infected cells, as well as low but significant numbers of double infected cells (S6 Fig). We did not observe differences in timing of the onset of viral gene expression between singly infected and the CFP/YFP co-infected cells, indicating that co-infecting viruses did not show cooperativity in the onset of viral gene expression in primary CD4+ T cells and confirming our results in MT4 cells.
Since cooperativity between virions could not account for the earlier onset of HIV gene expression, we asked whether multiple infections per cell accelerated onset of gene expression by a first-past-the-post mechanism, where the earliest virus to express sets the time of infection (Fig 4A). This mechanism operates if: 1) Each integrated virus has a stochastically set time to viral protein expression. 2) Infections proceed independently. 3) A single expressed virion is sufficient to make use of target cell resources so that the target cell becomes infectious [26].
We reasoned that if a cell is infected by n>1 virions, the virion that first completes the replication cycle sets the time to infection. If each infection is independent, the distribution of the time to infection given n virions per cell is:
(1) |
Here p(t) is the distribution of the time to viral gene expression given a single virion per cell approximated by a Gamma distribution, and Q(t) is the corresponding cumulative distribution. In an infection with an average MOI m, the cells will be infected with a number of virions which is Poisson distributed around m and can be modelled by the average of Eq 1 over different n with Poisson weights (excluding n = 0). The distribution of the time to viral gene expression at m is then given by:
(2) |
where the pre-factor normalizes the distribution. We determined the shape and scale parameters of p(t) by jointly fitting the time series data for the multiple MOI infections to Eq 2. The model fits the data well for MOI 0.1, 0.5, 2, 4 with only the two parameters of the Gamma distribution, indicating that our model of independent stochastic infections can explain the acceleration at high MOI (Fig 4B).
To determine the effective MOI for coculture infections, we fitted the time course data to Eq 2 using the shape and scale parameters of the Gamma distribution determined by a fit to the cell-free data, approximating n = 1 for cell-free infections (Fig 4C). We obtained that the acceleration of viral gene expression with coculture was predicted by an effective MOI of 4.6 per cell.
Coculture infection leads to earlier onset of HIV gene expression in primary human cells
To examine whether the earlier onset of HIV gene expression observed in the cell line also occurs in primary cells, we used coculture with autologous infected donor cells or cell-free virus to infect peripheral blood mononuclear cells (PBMCs) derived from healthy donors. As with the cell lines, donor cells were separated from target cells by labelling them with a vital stain. The fraction of infected target cells at different times post-infection was quantified by detection of the viral p24 protein, made as part of the HIV Gag polyprotein, using flow cytometry (Fig 5A). Virus was washed away after 2 hours in both cell-free and coculture infections, and ATV added to prevent additional infection cycles. ATV was used at a concentration sufficient to inhibit more than 99% of coculture infections (S3C Fig). Coculture dramatically accelerated the onset of HIV gene expression as measured by the detection of the HIV Gag protein relative to cell-free infection in primary human cells from 34.2±9.1 hours to 22.1±9.3 hours (mean±std). This constituted a decrease of 35% in the mean time to detectable HIV Gag expression (Fig 5B). Based on the cell-free distribution, the best-fit MOI per cell in coculture infection to recapitulate the difference in viral expression onset was 5.0 (Fig 5B, dashed red line).
PBMCs contain monocytes and other cells which may complicate interpretation of these results. To investigate whether T cell to T cell transmission was sufficient for the faster onset of viral gene expression, we repeated the experiment with purified CD4+ T cells (Fig 5B Inset and S7 Fig). We confirmed that cell-to-cell transmission between autologous T cells resulted in a more rapid onset of viral gene expression relative to cell-free infection.
We next proceeded to compare our predicted number of infections per cell using the timing of the onset of viral gene expression to that obtained by a second method. We have previously developed an approach to predict the number of infections per cell in cell-to-cell spread based on the reduced sensitivity to antiretroviral drugs relative to cell-free infection [27]. We therefore performed the PBMC infection in the presence of the integrase inhibitor raltegravir (RAL). As in the timing experiments, we used a 2-hour infection window. Coculture infection decreased sensitivity to RAL (Fig 6), consistent with our previous work and that of others showing that cell-to-cell spread decreases sensitivity to HIV inhibitors. For PBMC infection, IC50 of cell-free infection was 1.9nM and the maximum concentration of RAL used (60nM) decreased infection 12.2-fold. In contrast, IC50 of infection was 10nM and infection was reduced 2.6-fold at the same RAL concentration when transmission was by coculture. Reduced RAL sensitivity of coculture infection was also confirmed with transmission between purified autologous CD4+ T cells using a 2-hour infection window (Fig 6 Inset). In this case, 60nM RAL reduced cell-free infection by 33.3-fold. In contrast, coculture infection was reduced 3.6-fold. The best-fit MOI per cell needed to account for the reduced sensitivity of PBMC coculture infection to RAL was 4.8, which was similar to the number of virions predicted using infection timing under the same infection conditions.
Discussion
We have observed faster onset of viral gene expression in coculture infection containing cell-to-cell spread of HIV relative to cell-free HIV infection. The earlier onset of viral gene expression in coculture was lost when target cells were separated from donor cells by a transwell membrane. A faster virus cycle in cell-to-cell spread relative to the non-directed, cell-free mode of infection has been previously observed directly [2, 13, 41] and inferred through modelling of infection dynamics [39, 40]. Here we used time-lapse microscopy of HIV infection to directly quantify and investigate the mechanism behind the faster onset of viral gene expression. We minimized possible differences between cell-to-cell spread and cell-free infection in the extracellular transit time from donor to target cell by limiting the time window of transmission to 2 hours. We have also minimized any contribution of virus sequence to different viral gene expression dynamics by using viruses with identical sequences derived from a molecular clone. Hence, variability in gene expression is a result of the interaction of the virus with the host cell. After exclusion of donor-target cell fusions, we found a minimum time for early viral protein expression in both infection modes, corresponding to a period of intracellular delay indicative of true infection [53–55]. We found that we could recapitulate the faster onset of viral gene expression by increasing the MOI of cell-free virus, and that there was no evidence for cooperativity or interference between co-infecting viruses. There was also no evidence for trans-acceleration of HIV gene expression onset from the surrounding infected cells.
Previous studies on cell-to-cell spread have concentrated on understanding the mechanisms by which cell-to-cell transmission occurs, and such mechanisms may lead to a faster onset of the expression of viral genes in the infected target cell in addition to making the infection more efficient. For example, it has been reported that the infected donor cell rapidly polarizes to the site of contact with the target cell [20] and that the subsequent transmission to the target cell occurs quickly [4, 18, 59, 60], though viral membrane fusion has been reported to be slower in cell-to-cell spread relative to cell-free infection [16]. Hence, a faster onset of HIV gene expression in cell-to-cell spread may be strictly mechanistic, due to more rapid entry of the virus. In this case, it would be expected that increasing cell-free MOI would not lead to faster onset, as increasing the MOI does not change the attachment and entry route. Since our data shows that cell-free MOI does control the onset of HIV gene expression, mechanistic factors such as more rapid entry in cell-to-cell spread are unlikely to play a major role.
Given multiple infections of the same cell in cell-to-cell spread, we would expect three possibilities of how co-infecting viruses could interact at the level of viral gene expression [61]. The first would be synergistic/cooperative interactions, where expression of one virus amplifies the expression of a co-infecting virus. The second would be no interaction, and the third would be that co-infecting viruses may compete for cellular resources and hence expression of one virus would interfere with the expression of co-infecting viruses. For example, comparing 10 co-infecting viruses to 10 infections identical in every way except occurring in 10 different cells, cooperativity would lead to the cell with 10 co-infecting viruses to show more rapid onset of viral gene expression relative to any one of the 10 single infections. No interaction between viruses would lead to the onset in the cell with 10 co-infecting viruses to be as fast as the fastest cell among the 10 singly infected cells, what we term a first-past-the-post mechanism. Interference or antagonism would lead to the cell with 10 co-infecting viruses to show a slower onset of viral gene expression than the fastest cell among the 10 singly infected cells, and possibly slower than the other singly infected cells.
Interactions between co-infecting viral genomes in HIV and other viruses have been extensively documented. For example, co-infecting viruses share post-integration components by a process known as complementation [62–66]. Hence, we would have predicted that there is at least some cooperativity in viral gene expression between co-infecting viruses as a result of the Tat positive feedback loop, as intracellular Tat concentration should increase with the number of expressed proviruses [42–44]. This mechanism of cooperativity would be expected to manifest as faster onset of viral gene expression since the delay to build up Tat levels by basal transcription should be reduced [44]. However, no detectable differences in the timing of the onset of HIV gene expression upon co-infection of YFP-HIV with unlabeled virus and no detectable differences when primary CD4+ cells were co-infected with two viruses argues against the presence of cooperativity at the onset of gene expression. Likewise, no interference was observed. Instead, we found that the mechanism most consistent with the faster onset of viral gene expression was that multiple infections per cell in coculture infection resulted in a pool of viruses which express viral genes at different times post-infection. The virus with the fastest onset of gene expression from this pool sets the start time for the generation of viral components by the infected cell.
We note that the lack of cooperativity as detected at the onset of HIV gene expression does not mean that co-infecting viruses do not interact, and interactions may occur later in the virus cycle. For example, interference may be expected to occur close to the time of peak virus production, where co-infecting viruses could compete for limited cellular resources to assemble virions [26, 67]. Such effects would influence the number of virions produced, but not the onset of gene expression as measured here.
We compared the predicted number of infections per cell based on the timing of the viral cycle to that predicted by the decreased sensitivity of coculture infection to an antiretroviral drug. The MOI per cell in PBMC coculture infection was predicted by timing to be 5.0 infectious viruses. This was similar to the predicted MOI based on the degree of insensitivity of PBMC coculture infection to the antiretroviral RAL (MOI = 4.8). Interestingly, the drug insensitivity of cell-to-cell spread to RAL was maintained despite keeping infection to one virus cycle using ATV. This indicates that the faster virus cycle of cell-to-cell spread is not necessary for drug insensitivity. However, a faster virus cycle may contribute to replication in the face of drug by amplifying an expanding infection.
Assuming that faster viral gene expression leads to more rapid viral dynamics, a more rapid onset of the viral cycle may confer a fitness advantage of rapid initial expansion, or transmission where the turnover rate of infected cells is high [2, 68]. Reasons for high turnover may include targeting of infected cells by cytotoxic T lymphocytes [69, 70], or a limited infection window due to bystander killing of target cells [71–74], all operating in environments such as lymph nodes where cell-to-cell infection is likely to occur [29, 31, 71, 73]. In exponential expansion at the R0 observed during primary HIV infection (~8, [75]), decreasing the infection cycle time by one quarter can lead to a 2 order of magnitude increase in the number of infected cells over several weeks. A large reservoir would be a barrier to a prolonged period of treatment interruption without rebound or to a permanent cure [76–81]. Thus, a faster viral cycle may seed a larger HIV reservoir, which would be more difficult to eliminate. However, if the most rapid virus cycle rate gives the highest fitness advantage, then cooperativity in gene expression would have been expected to evolve. Yet it does not seem to occur, perhaps indicating drawbacks to cooperativity such as more rapid cytotoxicity, or decreased ability of the virus to enter a quiescent state [82–85].
Materials and Methods
Ethical statement
Blood was obtained from adult healthy volunteers after written informed consent (University of KwaZulu-Natal Institutional Review Board approval BE022/13).
Inhibitors, viruses and cells
The following reagents were obtained through the AIDS Research and Reference Reagent Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health: the antiretroviral drugs ATV and RAL; Rev-CEM cells from Y. Wu and J. Marsh [48]; MT-4 cells from D. Richman [58]; HIV expression plasmid pNL4-3 from M. Martin [86] and pNL-AD8 from E. Freed [87]. The NL4-3YFP molecular clone was a gift from D. Levy [57]. Cell-free viruses were produced by transfection of HEK293 cells (ATCC) with molecular clones using TransIT-LT1 (Mirus) or Fugene HD (Roche) transfection reagents. Supernatant containing released virus was harvested after two days of incubation and filtered through a 0.45μm filter (Corning). The number of virus genomes in viral stocks was determined using the RealTime HIV-1 viral load test (Abbott Diagnostics). To produce the E7 clone, RevCEM cells were subcloned at single cell density and screened for the fraction of GFP expressing cells upon HIV infection using microscopy. To produce the G2 clone, E7 cells were stably infected with the mCherry gene under the control of the EF-1α promoter on a pHAGE2 based lentiviral vector (gift from A. Balazs), subcloned, and screened for clones with >99% mCherry positive cells. Similarly, the MT4-mCherry cell line was created by infecting MT4-cells with the pHAGE2 lentiviral vector expressing mCherry. PBMCs were isolated by density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich). CD4+ cells were positively selected using CD4 Microbeads loaded onto MACS separation columns according to manufacturer’s instructions (Miltenyi Biotec). Culture and experiments were performed in complete RPMI 1640 medium supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids (Lonza), and 10% heat-inactivated FBS (Hyclone). Primary cells were additionally supplemented with IL-2 at 5ng/ml (PeproTech). PBMCs and CD4+ T cells were activated at 2*106 per ml density for one (donor cells) or three days (target cells) with PHA at 10μg/ml (Sigma-Aldrich).
Infection
For infection of RevCEM clones, 5x105 cells/ml E7 reporters were infected with 2x108 NL4-3 viral copies/ml (20ng p24 equivalent [88]) and used as infected donor cells. Infected and uninfected donors were incubated for two days, then stained with CellTrace Far Red (CTFR, Thermo Fisher Scientific) at 1μM and washed according to manufacturer’s instructions. G2 reporters at 5x105 cells/ml were either cocultured with 1:20 infected donor cells, or 1:20 uninfected donor cells and 109 NL4-3 viral copies/ml cell free virus. For RevCEM coculture experiments with cells infected with CCR5 tropic HIV, activated CD4+ cells at a concentration of 106 cells/ml were infected with 2x108 NL-AD8 viral copies per ml. Infected and uninfected CD4+ cells were incubated for two days. After two days, CD4+ cells were stained with CTFR as above. G2 cells were then infected with 109 copies/ml cell-free NL4-3, and cocultured with either infected or uninfected CD4+ cells, equal in number to the number of NL4-3 infected E7 cells added to the coculture positive control. For MT4 infections, cells were infected at a density of 5x105 cells/ml with 1.2x108 (MOI = 0.1) to 5x109 (MOI = 4) viral copies per ml of NL4-3YFP. For cooperativity experiments, MT4 cells were infected with 4x108 NL4-3YFP alone (MOI = 0.3) or co-infected with 4x108 copies of NL4-3YFP (MOI = 0.3) and 5x109 copies NL4-3 (MOI = 8). For PBMC infections, one day activated cells at a concentration of 106 cells/ml were used as donors and infected with 2x108 NL4-3 viral copies per ml. Donor cells were incubated for two days, and were separated from target cells by labelling them with CTFR or with carboxyfluorescein succinimidyl ester at 1μM (CFSE, Thermo Fisher Scientific) vital stain. CTFR or CFSE positive cells were excluded from the analysis, being either donors or donor-target fusions. Three day activated PBMC target cells at 106 cells/ml were then infected with either 1:10 infected donor cells, or with 1:10 uninfected donor cells and 5x108 copies of cell-free NL4-3. All cell-free and coculture infections of target cells were washed twice in medium after a two hour incubation with cell-free virus or infected donors, then resuspended in fresh growth medium with ATV. In the RAL sensitivity experiments, RAL was pre-incubated with target cells 4 hours before infection. Experiments comparing drug sensitivity and viral expression onset of co-culture and cell-free infections in primary CD4+ T cells were performed as with PBMCs. For experiments examining cooperativity in CD4+ T cells, infection with NL4-3YFP and NL4-3CFP was performed by adding 5x108 cell-free virions of each strain per 106 cells. CD4+ T cells were washed twice 2 hours post-infection and ATV was added as for PBMCs.
Staining and flow cytometry
PBMCs and CD4+ cells infected with NL4-3wt or NL-AD8 were strained with anti-p24 FITC-conjugated or PE-conjugated antibody (KC57, Beckman Coulter) using the Cytofix/Cytoperm and the Perm/Wash buffers (BD Biosciences) according to manufacturer’s instructions. Cells were acquired with a FACSAriaIII or FACSCaliber machine (BD Biosciences) using 488 and 640nm laser lines. A minimum of 105 cells per sample were acquired. Results were analyzed with FlowJo 10.0.8 software. For CFP/YFP co-infection experiments, cells were acquired with a FACSAriaIII using the 405nm laser line for CFP, and 488nm laser line for YFP.
Time-lapse microscopy
Cell density was reduced to 7x104 cells/ml and cells were attached to ploy-l-lysine (Sigma-Aldrich) coated 6-well optical plates (MatTek). Cell-free and coculture infections were imaged in tandem using a Metamorph-controlled Nikon TiE motorized microscope with a 20x, 0.75 NA phase objective in a biosafety level 3 facility. Excitation sources were 488 (GFP, YFP), 561 (mCherry), or 640 nm (CTFR) laser lines and emission was detected through a Semrock Brightline quad band 440–40 /521-21/607-34/700-45 nm filter. Images were captured using an 888 EMCCD camera (Andor). Temperature (37°C), humidity and CO2 (5%) were controlled using an environmental chamber (OKO Labs). Fields of view were captured every 30 minutes and a minimum of 1000 target cells were acquired per condition. Threshold for detection of the onset of HIV gene expression was set so that no positive cells were detected in the uninfected control. Cells with above threshold expression were scored as positive.
Transwell assay
Cells were either infected by coculture in the lower compartment of a 6-well transwell plate with 0.4 μm pores (Costar) or separated across the membrane. To maintain a similar fraction of infected cells, 10-fold more donors were used when infection was across the membrane relative to coculture. Cell-free infection was performed in the lower compartment or across the membrane. After six-hour incubation, infection was washed, ATV added, and cells transferred to optical plates for imaging, keeping the donors in their initial compartments but not in the focal plane.
Image analysis
Movies were analyzed using custom code developed with the Matlab R2014a Image Analysis Toolbox. Images in the mCherry channel were thresholded to obtain images, and the imfindcircle function used to detect round objects within the cell radius range. Cell centers were found. GFP and CTFR signals underwent the same binary thresholding. The number of mCherry positive 16 pixel2 squares around the cell centers, negative for fluorescence in the CTFR channel and positive for fluorescence in the GFP channel, was used as the number of infected target cells. YFP signal in MT4 mCherry cells was analyzed in the same way except no CTFR stain was used, as infection was by cell-free virus.
Normalization to distribution tail
For time-lapse experiments, data was normalized to compare infection between experimental conditions that had a similar, but not exactly equal number of infected cells. Normalization was by the average of the fraction of infected target cells during the last three hours to accurately capture the maximum infection level at the end of the viral cycle. Normalization by the maximum number of infected target cells was found to be noisy since it was sensitive to outlier values in the data.
Modeling
Fitting of time-lapse data was done using a custom Python script using the Powell minimization algorithm from scipy (S1 Script). For drug sensitivity modelling, cell-free infection in the presence of increasing RAL concentrations was parametrized using the relation
(3) |
where d denotes the decrease in the experimentally determined fraction of infected cells relative to no drug, D is the drug concentration, and IC 50, and h are the open parameters for the fit [89]. The number of infectious viruses per target cell (m) delivered in coculture infection was determined by fitting
(4) |
where Tx is the experimentally determined number of coculture infected cells in the presence of different RAL concentrations normalized by the number of infected cells in the absence of RAL [27], and d is determined for each drug concentration by Eq 3. Script is provided (S2 Script).
Supporting Information
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
AS is supported by a Human Frontiers Science Program Career Development Award CDA 00050/2013. MB is supported by a Fonds Solidarité Santé Navale Fellowship. RAN is supported by the European Research Council through grant Stg. 260686. LJ is supported by a fellowship from the South African National Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Baxter AE, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, et al. Macrophage infection via selective capture of HIV-1-infected CD4+ T cells. Cell Host Microbe. 2014. December 10;16(6):711–21. 10.1016/j.chom.2014.10.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Gummuluru S, KewalRamani VN, Emerman M. Dendritic cell-mediated viral transfer to T cells is required for human immunodeficiency virus type 1 persistence in the face of rapid cell turnover. J Virol. 2002. November;76(21):10692–701. 10.1128/JVI.76.21.10692-10701.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Hashimoto M, Bhuyan F, Hiyoshi M, Noyori O, Nasser H, Miyazaki M, et al. Potential Role of the Formation of Tunneling Nanotubes in HIV-1 Spread in Macrophages. J Immunol. 2016. February 15;196(4):1832–41. 10.4049/jimmunol.1500845 [DOI] [PubMed] [Google Scholar]
- 4. Hubner W, McNerney GP, Chen P, Dale BM, Gordon RE, Chuang FY, et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science. 2009. March 27;323(5922):1743–7. 10.1126/science.1167525 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med. 2004. January 19;199(2):283–93. 10.1084/jem.20030648 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Jolly C, Sattentau QJ. Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains. J Virol. 2007. August;81(15):7873–84. 10.1128/JVI.01845-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Jolly C, Welsch S, Michor S, Sattentau QJ. The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse. PLoS Pathog. 2011. September;7(9):e1002226 10.1371/journal.ppat.1002226 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol. 2010. April;84(7):3516–27. 10.1128/JVI.02651-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol. 2008. November;6(11):815–26. 10.1038/nrmicro1972 [DOI] [PubMed] [Google Scholar]
- 10. Sherer NM, Jin J, Mothes W. Directional spread of surface-associated retroviruses regulated by differential virus-cell interactions. J Virol. 2010. April;84(7):3248–58. 10.1128/JVI.02155-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, Mothes W. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat Cell Biol. 2007. March;9(3):310–5. 10.1038/ncb1544 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol. 2008. February;10(2):211–9. 10.1038/ncb1682 [DOI] [PubMed] [Google Scholar]
- 13. Carr JM, Hocking H, Li P, Burrell CJ. Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology. 1999. December 20;265(2):319–29. 10.1006/viro.1999.0047 [DOI] [PubMed] [Google Scholar]
- 14. Dale B, McNerney GP, Thompson DL, Hubner W, Huser T, Chen BK. Visualizing cell-to-cell transfer of HIV using fluorescent clones of HIV and live confocal microscopy. J Vis Exp. 2010(44). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Dale BM, McNerney GP, Hubner W, Huser TR, Chen BK. Tracking and quantitation of fluorescent HIV during cell-to-cell transmission. Methods. 2011. January;53(1):20–6. 10.1016/j.ymeth.2010.06.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Dale BM, McNerney GP, Thompson DL, Hubner W, de Los Reyes K, Chuang FY, et al. Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion. Cell Host Microbe. 2011. December 15;10(6):551–62. 10.1016/j.chom.2011.10.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Duncan CJ, Russell RA, Sattentau QJ. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS. 2013. September 10;27(14):2201–6. 10.1097/QAD.0b013e3283632ec4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Duncan CJ, Williams JP, Schiffner T, Gartner K, Ochsenbauer C, Kappes J, et al. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol. 2014. February;88(4):2025–34. 10.1128/JVI.03245-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Groot F, Welsch S, Sattentau QJ. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood. 2008. May 1;111(9):4660–3. 10.1182/blood-2007-12-130070 [DOI] [PubMed] [Google Scholar]
- 20. Groppelli E, Starling S, Jolly C. Contact-induced mitochondrial polarization supports HIV-1 virological synapse formation. J Virol. 2015. January;89(1):14–24. 10.1128/JVI.02425-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Gummuluru S, Pina Ramirez NG, Akiyama H. CD169-dependent cell-associated HIV-1 transmission: a driver of virus dissemination. J Infect Dis. 2014. December 15;210 Suppl 3:S641–7. 10.1093/infdis/jiu442 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Monel B, Beaumont E, Vendrame D, Schwartz O, Brand D, Mammano F. HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores. J Virol. 2012. April;86(7):3924–33. 10.1128/JVI.06478-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007. December 14;131(6):1059–71. 10.1016/j.cell.2007.10.014 [DOI] [PubMed] [Google Scholar]
- 24. Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, et al. Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes. AIDS. 2014. March 13;28(5):667–77. 10.1097/QAD.0000000000000193 [DOI] [PubMed] [Google Scholar]
- 25. Agosto LM, Uchil PD, Mothes W. HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. Trends Microbiol. 2015. May;23(5):289–95. 10.1016/j.tim.2015.02.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Dixit NM, Perelson AS. HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci U S A. 2005. June 7;102(23):8198–203. 10.1073/pnas.0407498102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011. September 1;477(7362):95–8. 10.1038/nature10347 [DOI] [PubMed] [Google Scholar]
- 28. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci U S A. 2000. December 19;97(26):14566–71. 10.1073/pnas.97.26.14566 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, et al. Recombination: Multiply infected spleen cells in HIV patients. Nature. 2002. July 11;418(6894):144 10.1038/418144a [DOI] [PubMed] [Google Scholar]
- 30. Del Portillo A, Tripodi J, Najfeld V, Wodarz D, Levy DN, Chen BK. Multiploid inheritance of HIV-1 during cell-to-cell infection. J Virol. 2011. May 4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Law KM, Komarova NL, Yewdall AW, Lee RK, Herrera OL, Wodarz D, et al. In Vivo HIV-1 Cell-to-Cell Transmission Promotes Multicopy Micro-compartmentalized Infection. Cell Rep. 2016. June 21;15(12):2771–83. 10.1016/j.celrep.2016.05.059 [DOI] [PubMed] [Google Scholar]
- 32. Agosto LM, Zhong P, Munro J, Mothes W. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog. 2014. February;10(2):e1003982 10.1371/journal.ppat.1003982 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Titanji BK, Aasa-Chapman M, Pillay D, Jolly C. Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology. 2013;10:161 10.1186/1742-4690-10-161 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 2012;8(4):e1002634 10.1371/journal.ppat.1002634 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Reh L, Magnus C, Schanz M, Weber J, Uhr T, Rusert P, et al. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. PLoS Pathog. 2015. July;11(7):e1004966 10.1371/journal.ppat.1004966 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Schiffner T, Sattentau QJ, Duncan CJ. Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine. 2013. December 2;31(49):5789–97. 10.1016/j.vaccine.2013.10.020 [DOI] [PubMed] [Google Scholar]
- 37. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, et al. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One. 2013;8(1):e53138 10.1371/journal.pone.0053138 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Sigal A, Baltimore D. As good as it gets? The problem of HIV persistence despite antiretroviral drugs. Cell Host Microbe. 2012. August 16;12(2):132–8. 10.1016/j.chom.2012.07.005 [DOI] [PubMed] [Google Scholar]
- 39. Komarova NL, Anghelina D, Voznesensky I, Trinite B, Levy DN, Wodarz D. Relative contribution of free-virus and synaptic transmission to the spread of HIV-1 through target cell populations. Biol Lett. 2013. February 23;9(1):20121049 10.1098/rsbl.2012.1049 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Iwami S, Takeuchi JS, Nakaoka S, Mammano F, Clavel F, Inaba H, et al. Cell-to-cell infection by HIV contributes over half of virus infection. Elife. 2015;4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol. 1993. April;67(4):2182–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. Embo J. 2001. April 2;20(7):1726–38. 10.1093/emboj/20.7.1726 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Strebel K. Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. Aids. 2003;17 Suppl 4:S25–34. [DOI] [PubMed] [Google Scholar]
- 44. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 2005. July 29;122(2):169–82. 10.1016/j.cell.2005.06.006 [DOI] [PubMed] [Google Scholar]
- 45. Muratori C, Cavallin LE, Kratzel K, Tinari A, De Milito A, Fais S, et al. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe. 2009. September 17;6(3):218–30. 10.1016/j.chom.2009.06.009 [DOI] [PubMed] [Google Scholar]
- 46. Weinberger LS. A minimal fate-selection switch. Curr Opin Cell Biol. 2015. December;37:111–8. 10.1016/j.ceb.2015.10.005 [DOI] [PubMed] [Google Scholar]
- 47. Marini B, Kertesz-Farkas A, Ali H, Lucic B, Lisek K, Manganaro L, et al. Nuclear architecture dictates HIV-1 integration site selection. Nature. 2015. May 14;521(7551):227–31. 10.1038/nature14226 [DOI] [PubMed] [Google Scholar]
- 48. Wu Y, Beddall MH, Marsh JW. Rev-dependent indicator T cell line. Curr HIV Res. 2007. July;5(4):394–402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Fischer U, Huber J, Boelens WC, Mattaj IW, Luhrmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell. 1995. August 11;82(3):475–83. [DOI] [PubMed] [Google Scholar]
- 50. Fischer U, Meyer S, Teufel M, Heckel C, Luhrmann R, Rautmann G. Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA. Embo J. 1994. September 1;13(17):4105–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol. 1998;52:491–532. 10.1146/annurev.micro.52.1.491 [DOI] [PubMed] [Google Scholar]
- 52. Holmes M, Zhang F, Bieniasz PD. Single-Cell and Single-Cycle Analysis of HIV-1 Replication. PLoS Pathog. 2015. June;11(6):e1004961 10.1371/journal.ppat.1004961 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Dixit NM, Markowitz M, Ho DD, Perelson AS. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther. 2004. April;9(2):237–46. [PubMed] [Google Scholar]
- 54. Mittler JE, Markowitz M, Ho DD, Perelson AS. Improved estimates for HIV-1 clearance rate and intracellular delay. Aids. 1999. July 30;13(11):1415–7. [DOI] [PubMed] [Google Scholar]
- 55. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996. March 15;271(5255):1582–6. [DOI] [PubMed] [Google Scholar]
- 56. Parker T. The Gamma Distribution as Model of Multistep Processes: University of Michigan, Department of psychology; 1974. [Google Scholar]
- 57. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A. 2004. March 23;101(12):4204–9. 10.1073/pnas.0306764101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985. August 9;229(4713):563–6. [DOI] [PubMed] [Google Scholar]
- 59. Chen P, Hubner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol. 2007. November;81(22):12582–95. 10.1128/JVI.00381-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Russell RA, Martin N, Mitar I, Jones E, Sattentau QJ. Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology. 2013. August 15;443(1):143–9. 10.1016/j.virol.2013.05.005 [DOI] [PubMed] [Google Scholar]
- 61. Chait R, Craney A, Kishony R. Antibiotic interactions that select against resistance. Nature. 2007. April 5;446(7136):668–71. 10.1038/nature05685 [DOI] [PubMed] [Google Scholar]
- 62. Andino R, Domingo E. Viral quasispecies. Virology. 2015. May;479–480:46–51. 10.1016/j.virol.2015.03.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Crowder S, Kirkegaard K. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nat Genet. 2005. July;37(7):701–9. 10.1038/ng1583 [DOI] [PubMed] [Google Scholar]
- 64. Froissart R, Wilke CO, Montville R, Remold SK, Chao L, Turner PE. Co-infection weakens selection against epistatic mutations in RNA viruses. Genetics. 2004. September;168(1):9–19. 10.1534/genetics.104.030205 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Gutierrez S, Pirolles E, Yvon M, Baecker V, Michalakis Y, Blanc S. The Multiplicity of Cellular Infection Changes Depending on the Route of Cell Infection in a Plant Virus. J Virol. 2015. September;89(18):9665–75. 10.1128/JVI.00537-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Gutierrez S, Yvon M, Thebaud G, Monsion B, Michalakis Y, Blanc S. Dynamics of the multiplicity of cellular infection in a plant virus. PLoS Pathog. 2010;6(9):e1001113 10.1371/journal.ppat.1001113 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Cummings KW, Levy DN, Wodarz D. Increased burst size in multiply infected cells can alter basic virus dynamics. Biol Direct. 2012;7:16 10.1186/1745-6150-7-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Gummuluru S, Kinsey CM, Emerman M. An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol. 2000. December;74(23):10882–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012. March 23;36(3):491–501. 10.1016/j.immuni.2012.01.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987. July 23–29;328(6128):345–8. 10.1038/328345a0 [DOI] [PubMed] [Google Scholar]
- 71. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010. November 24;143(5):789–801. 10.1016/j.cell.2010.11.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014. January 23;505(7484):509–14. 10.1038/nature12940 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med. 1995. February;1(2):129–34. [DOI] [PubMed] [Google Scholar]
- 74. Galloway NL, Doitsh G, Monroe KM, Yang Z, Munoz-Arias I, Levy DN, et al. Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-Derived CD4 T Cells. Cell Rep. 2015. September 8;12(10):1555–63. 10.1016/j.celrep.2015.08.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol. 2010. June;84(12):6096–102. 10.1128/JVI.00127-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS. 2012. June 19;26(10):1261–8. 10.1097/QAD.0b013e328353f3f1 [DOI] [PubMed] [Google Scholar]
- 77. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014. September 2;161(5):319–27. 10.7326/M14-1027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A. 2014. September 16;111(37):13475–80. 10.1073/pnas.1406663111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013. June 15;381(9883):2109–17. 10.1016/S0140-6736(13)60104-X [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013. July;254(1):326–42. 10.1111/imr.12065 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Williams JP, Hurst J, Stohr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014;3:e03821 10.7554/eLife.03821 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82. Rouzine IM, Razooky BS, Weinberger LS. Stochastic variability in HIV affects viral eradication. Proc Natl Acad Sci U S A. 2014. September 16;111(37):13251–2. 10.1073/pnas.1413362111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Rouzine IM, Weinberger AD, Weinberger LS. An evolutionary role for HIV latency in enhancing viral transmission. Cell. 2015. February 26;160(5):1002–12. 10.1016/j.cell.2015.02.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84. Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. A hardwired HIV latency program. Cell. 2015. February 26;160(5):990–1001. 10.1016/j.cell.2015.02.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85. Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. The viral protein Tat can inhibit the establishment of HIV-1 latency. J Virol. 2012. March;86(6):3253–63. 10.1128/JVI.06648-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986. August;59(2):284–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Freed EO, Englund G, Martin MA. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol. 1995. June;69(6):3949–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88. Bourinbaiar AS. HIV and gag. Nature. 1991. January 10;349(6305):111. [DOI] [PubMed] [Google Scholar]
- 89. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008. July;14(7):762–6. 10.1038/nm1777 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.